The weight loss drug Wegovy has been associated with an increase in gastrointestinal problems, which can be serious in some cases, according to an updated warning label from the U.S. Food and Drug Administration.
In late November, the FDA added a warning to the label of a highly popular GLP-1 drug. The updated label states that participants in clinical trials of the drug were more likely to report “serious gastrointestinal side effects.”
The FDA warns about people with severe gastroparesis, a condition in which the stomach can’t move food fast enough, which can cause nausea and pain. Should not take weight loss drugs.
mild gastrointestinal reaction, such as nausea and constipation are the most common side effects of GLP-1 receptor agonists such as Wegovy.
However, the new warning label mentions more serious side effects. The label currently advises patients to consult a doctor if they have severe stomach problems or if their stomach problems persist.
FDA did not update warning labels for other GLP-1 drugs, including Ozempic, Rybelsus, Saxenda, Victoza, Mounjaro, and Zepbound. At least one Zepbound already included a warning label for people with severe gastroparesis and severe gastrointestinal disease.
GLP-1 is sometimes prescribed for weight loss, diabetes treatment, and other conditions. According to , about 12% of American adults report having taken the drug at some point. KFF Health News May 2024 Poll.
The latest Wegovy update comes on the heels of another recently added warning. On November 1, the FDA warned that people taking GLP-1 may be at increased risk of inhaling stomach contents into the lungs while under anesthesia.
That’s because GLP-1, such as Wegovy and Ozempic, slows gastric emptying, allowing food and gastric juices to stay in the stomach longer. the doctor said dallas morning news Earlier this month, they announced that they had known for some time that there was an increased risk from anesthesia for patients taking GLP-1.
More serious side effects, such as gastroparesis, were also fairly well documented before the FDA recently updated its warning on Wegovy. 2023 Survey We found that GLP-1 was associated with an increased risk of gastroparesis. additional research Announced in 2024 I found a similar link.
